Concepedia

Ronald J. Hinklin

RJ

15

Publications

1.1K

Citations

14

H-Index

2001

Active since

Affiliations

Array BioPharma (United States)(Current)

Amgen (United States)

University of Wisconsin–Madison

Eli Lilly (United States)

Mirati Therapeutics (United States)

Ronald J. Hinklin is an author at Array BioPharma (United States) specializing in pharmacology, medicine, and biochemistry.

ORCID

Top concepts

Publications per year

2001–2022

15

Publications

15

Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of Cancer

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · Journal of Medicinal Chemistry · 2020 · 559 citations · Full text

Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · ACS Medicinal Chemistry Letters · 2018 · 104 citations · Full text

Stereoselective N-Glycosylation by Staudinger Ligation

Yi He, Ronald J. Hinklin, Jiyoung Chang et al. · Organic Letters · 2004 · 88 citations

A Selective Estrogen Receptor Modulator Designed for the Treatment of Uterine Leiomyoma with Unique Tissue Specificity for Uterus and Ovaries in Rats

Conrad W. Hummel, Andrew G. Geiser, Henry U. Bryant et al. · Journal of Medicinal Chemistry · 2005 · 49 citations · Full text

Glycosyl Sulfonylcarbamates:  New Glycosyl Donors with Tunable Reactivity

Ronald J. Hinklin, Laura L. Kiessling · Journal of the American Chemical Society · 2001 · 47 citations

, , +10

Rows per page

1–5 of 15